A retrospective study to evaluate the clinical outcomes of biologic therapy in moderate-to-severe persistent asthma in a population with restricted medical care access
Latest Information Update: 20 Apr 2021
At a glance
- Drugs Benralizumab (Primary) ; Dupilumab (Primary) ; Mepolizumab (Primary) ; Omalizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 20 Apr 2021 New trial record
- 01 Mar 2021 Results presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology